Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Currently, Parallel Industries Inc. does not conduct substantial business operations. Historically, the company was involved in developing and commercializing various topically applied medications to treat cancer, alongside other therapeutic solutions for a range of medical conditions. Its strategic emphasis has typically covered the entire pharmaceutical process: from development and licensing to manufacturing and marketing of both prescription and over-the-counter products. Established in 1997, the firm is headquartered in Toronto, Canada, and was formerly known as Easton Pharmaceuticals Inc. before rebranding as Parallel Industries Inc. in December 2020.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.